Education
About Us
Working with TipRanks
Follow Us
GenSight Biologics SA (DE:G49N)
FRANKFURT:G49N
G49N Stock Chart & Stats
€0.06
-€0.04(-12.73%)
At close: 4:00 PM EST
€0.06
-€0.04(-12.73%)
Day’s Range― - ―
52-Week Range€0.06 - €0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)921.00
Market Cap
€18.06M
Enterprise Value€34.14M
Total Cash (Recent Filing)€270.00K
Total Debt (Recent Filing)€19.01M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Mar 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding220,890,400
10 Day Avg. Volume248
30 Day Avg. Volume921
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.96
Price to Sales (P/S)9.85
P/FCF Ratio-2.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.40Price Target Upside566.67% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Gene Therapy PlatformA dedicated gene-therapy platform focused on rare retinal diseases is a durable competitive asset: high scientific barriers, specialized know-how and regulatory exclusivities can create long-term market entry hurdles for competitors and underpin sustained premium partnerships and licensing value.
Multiple Potential Revenue StreamsA business model combining product sales, licensing, milestones and research collaborations diversifies cash sources. This structure can reduce single-product revenue dependence, enable milestone-driven non-linear cash inflows, and support long-term funding beyond direct sales.
Consistently High Gross Profit MarginSustained high gross margins indicate favorable unit economics for the therapy portfolio. If clinical success and scale occur, these margins support operating leverage, higher long-run profitability potential, and attractive economics for partners and royalty arrangements.
Bears Say
Negative Stockholders' EquityNegative equity signals structural balance-sheet weakness that limits financial flexibility. It increases refinancing risk, may raise counterparty and partner caution, and constrains investment capacity, making sustained R&D and commercialization more dependent on external capital raises.
Negative Operating Cash Flow And Financing ReliancePersistently negative operating cash flow forces dependence on external financing or partnerships to fund operations. This reliance risks dilution, timing gaps in access to capital, and can interrupt long-term programs if funding conditions tighten, impairing execution of clinical objectives.
Volatile And Steep Revenue DeclineLarge historical revenue volatility, including a steep decline, undermines predictability needed for scaling operations and forecasting. Unstable top-line trends complicate planning, reduce bargaining power with partners, and increase execution risk for long-term commercialization strategies.
G49N FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.06 and its highest was €0.24 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €18.06M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Mar 20, 2026 which is in 28 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2025. The company reported -€0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.05.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently Undervalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 220,890,400 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.986%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in DE:G49N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
G49N Stock 12 Month Forecast
Average Price Target
€0.40
▲(566.67% Upside)
Technical Analysis
Options Prices
Currently, No data available
---